2026년 8월 31일•1분 읽기
Samsung Bioepis, Proteina Expand AI Antibody Development
Samsung Bioepis and Proteina signed a license option agreement to advance AI‑driven antibody drug discovery from candidate identification to commercialization, building on a government AI project.